From: TSS ()
Subject: Summary and Implications of A Preliminary Assessment of Research and Development Needs and Gaps Relevant to BSE An Alberta Perspective
Date: January 17, 2006 at 1:17 pm PST
----- Original Message -----
From: Terry S. Singeltary Sr.
To: Bovine Spongiform Encephalopathy
Cc: AARIMAIL@gov.ab.ca
Sent: Tuesday, January 17, 2006 3:36 PM
Subject: re-Summary and Implications of A Preliminary Assessment of Research and Development Needs and Gaps Relevant to Bovine Spongiform Encephalopathy (BSE) An Alberta Perspective
Greetings AARI et al and especially to;
Prepared for: Alberta Agricultural Research Institute
Prepared by: Dr. Ralph Christian
Dr. Terry Church
Don Macyk
Freda Molenkamp
Derek Parker
IN the paper below, there is a grave error;
Summary and Implications of
A Preliminary Assessment of
Research and Development Needs and Gaps
Relevant to
Bovine Spongiform Encephalopathy (BSE)
An Alberta Perspective
Prepared for: Alberta Agricultural Research Institute
Prepared by: Dr. Ralph Christian
Dr. Terry Church
Don Macyk
Freda Molenkamp
Derek Parker
March 5, 2004
http://www.aari.ab.ca/sec/new_res/docs/BSE_summary.pdf
snip...
THE FOLLOWING IS NOT CORRECT;
· On BSE, there's not good evidence of a genetic predisposition. For humans, there is a
huge push towards that. What is the susceptibility of our population? That whole link of
variant CJD… there are new strains of BSE that look a lot more like variant CJD in their
51
pathology than the generic or mean strain of BSE. That work is out of Italy. We’re only
into the first chapter on prion diseases. As tests and levels of sensitivity improve, then
we will find a whole bunch more prion diseases out there that we have not yet identified. ...
THE CORRECT SHOULD READ AS FOLLOWS;
there are new strains of BSE that look a lot more like SPORADIC CJD in their
51
pathology than the generic or mean strain of BSE. That work is out of Italy. ...
THE following is the abstract of that study;
Medical Sciences
Identification of a second bovine amyloidotic spongiform encephalopathy: Molecular similarities with sporadic Creutzfeldt-Jakob disease
Cristina Casalone *, Gianluigi Zanusso , Pierluigi Acutis *, Sergio Ferrari , Lorenzo Capucci , Fabrizio Tagliavini ¶, Salvatore Monaco ||, and Maria Caramelli *
*Centro di Referenza Nazionale per le Encefalopatie Animali, Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna, 148, 10195 Turin, Italy; Department of Neurological and Visual Science, Section of Clinical Neurology, Policlinico G.B. Rossi, Piazzale L.A. Scuro, 10, 37134 Verona, Italy; Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia Romagna, Via Bianchi, 9, 25124 Brescia, Italy; and ¶Istituto Nazionale Neurologico "Carlo Besta," Via Celoria 11, 20133 Milan, Italy
Edited by Stanley B. Prusiner, University of California, San Francisco, CA, and approved December 23, 2003 (received for review September 9, 2003)
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are mammalian neurodegenerative disorders characterized by a posttranslational conversion and brain accumulation of an insoluble, protease-resistant isoform (PrPSc) of the host-encoded cellular prion protein (PrPC). Human and animal TSE agents exist as different phenotypes that can be biochemically differentiated on the basis of the molecular mass of the protease-resistant PrPSc fragments and the degree of glycosylation. Epidemiological, molecular, and transmission studies strongly suggest that the single strain of agent responsible for bovine spongiform encephalopathy (BSE) has infected humans, causing variant Creutzfeldt-Jakob disease. The unprecedented biological properties of the BSE agent, which circumvents the so-called "species barrier" between cattle and humans and adapts to different mammalian species, has raised considerable concern for human health. To date, it is unknown whether more than one strain might be responsible for cattle TSE or whether the BSE agent undergoes phenotypic variation after natural transmission. Here we provide evidence of a second cattle TSE. The disorder was pathologically characterized by the presence of PrP-immunopositive amyloid plaques, as opposed to the lack of amyloid deposition in typical BSE cases, and by a different pattern of regional distribution and topology of brain PrPSc accumulation. In addition, Western blot analysis showed a PrPSc type with predominance of the low molecular mass glycoform and a protease-resistant fragment of lower molecular mass than BSE-PrPSc. Strikingly, the molecular signature of this previously undescribed bovine PrPSc was similar to that encountered in a distinct subtype of sporadic Creutzfeldt-Jakob disease.
--------------------------------------------------------------------------------
C.C. and G.Z. contributed equally to this work.
||To whom correspondence should be addressed.
E-mail: salvatore.monaco@mail.univr.it .
www.pnas.org/cgi/doi/10.1073/pnas.0305777101
http://www.pnas.org/cgi/content/abstract/0305777101v1
ANOTHER STATEMENT I FIND VERY QUESTIONABLE IN THE ALBERTA PERSPECTIVE;
· In the 1940s and 50s there was evidence of spongiform encephalopathies in the mink
population (MSEs)…they were fed culled animals. This predates BSE issue.
WHAT ABOUT 1985 ???
FACTS ARE ;
Gerald Wells: Report of the Visit to USA, April-May 1989
snip...
The general opinion of those present was that BSE, as an
overt disease phenomenon, _could exist in the USA, but if it did,
it was very rare. The need for improved and specific surveillance
methods to detect it as recognised...
snip...
It is clear that USDA have little information and _no_ regulatory
responsibility for rendering plants in the US...
snip...
3. Prof. A. Robertson gave a brief account of BSE. The US approach
was to accord it a _very low profile indeed_. Dr. A Thiermann showed
the picture in the ''Independent'' with cattle being incinerated and thought
this was a fanatical incident to be _avoided_ in the US _at all costs_...
snip...
http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdf
To be published in the Proceedings of the
Fourth International Scientific Congress in
Fur Animal Production. Toronto, Canada,
August 21-28, 1988
Evidence That Transmissible Mink Encephalopathy
Results from Feeding Infected Cattle
R.F. Marsh* and G.R. Hartsough
•Department of Veterinary Science, University of Wisconsin-Madison, Madison,
Wisconsin 53706; and ^Emba/Creat Lakes Ranch Service, Thiensville, Wisconsin 53092
ABSTRACT
Epidemiologic investigation of a new incidence of
transmissible mink encephalopathy (TME) in Stetsonville, Wisconsin
suggests that the disease may have resulted from feeding infected
cattle to mink. This observation is supported by the transmission of
a TME-like disease to experimentally inoculated cattle, and by the
recent report of a new bovine spongiform encephalopathy in
England.
INTRODUCTION
Transmissible mink encephalopathy (TME) was first reported in 1965 by Hartsough
and Burger who demonstrated that the disease was transmissible with a long incubation
period, and that affected mink had a spongiform encephalopathy similar to that found in
scrapie-affecied sheep (Hartsough and Burger, 1965; Burger and Hartsough, 1965).
Because of the similarity between TME and scrapie, and the subsequent finding that the
two transmissible agents were indistinguishable (Marsh and Hanson, 1969), it was
concluded that TME most likely resulted from feeding mink scrapie-infecied sheep.
The experimental transmission of sheep scrapie to mink (Hanson et al., 1971)
confirmed the close association of TME and scrapie, but at the same time provided
evidence that they may be different. Epidemiologic studies on previous incidences of
TME indicated that the incubation periods in field cases were between six months and
one year in length (Harxsough and Burger, 1965). Experimentally, scrapie could not be
transmitted to mink in less than one year.
To investigate the possibility that TME may be caused by a (particular strain of
scrapie which might be highly pathogenic for mink, 21 different strains of the scrapie
agent, including their sheep or goat sources, were inoculated into a total of 61 mink.
Only one mink developed a progressive neurologic disease after an incubation period of
22 mon..s (Marsh and Hanson, 1979). These results indicated that TME was either caused
by a strain of sheep scrapie not yet tested, or was due to exposure to a scrapie-like agent
from an unidentified source.
OBSERVATIONS AND RESULTS
A New Incidence of TME. In April of 1985, a mink rancher in Stetsonville, Wisconsin
reported that many of his mink were "acting funny", and some had died. At this time, we
visited the farm and found that approximately 10% of all adult mink were showing
typical signs of TME: insidious onset characterized by subtle behavioral changes, loss of
normal habits of cleanliness, deposition of droppings throughout the pen rather than in a
single area, hyperexcitability, difficulty in chewing and swallowing, and tails arched over
their _backs like squirrels. These signs were followed by progressive deterioration of
neurologic function beginning with locomoior incoordination, long periods of somnolence
in which the affected mink would stand motionless with its head in the corner of the
cage, complete debilitation, and death. Over the next 8-10 weeks, approximately 40% of
all the adult mink on the farm died from TME.
Since previous incidences of TME were associated with common or shared feeding
practices, we obtained a careful history of feed ingredients used over the past 12-18
months. The rancher was a "dead stock" feeder using mostly (>95%) downer or dead dairy
cattle and a few horses. Sheep had never been fed.
Experimental Transmission. The clinical diagnosis of TME was confirmed by
histopaihologic examination and by experimental transmission to mink after incubation
periods of four months. To investigate the possible involvement of cattle in this disease
cycle, two six-week old castrated Holstein bull calves were inoculated intracerebrally
with a brain suspension from affected mink. Each developed a fatal spongiform
encephalopathy after incubation periods of 18 and 19 months.
DISCUSSION
These findings suggest that TME may result from feeding mink infected cattle and
we have alerted bovine practitioners that there may exist an as yet unrecognized
scrapie-like disease of cattle in the United States (Marsh and Hartsough, 1986). A new
bovine spongiform encephalopathy has recently been reported in England (Wells et al.,
1987), and investigators are presently studying its transmissibility and possible
relationship to scrapie. Because this new bovine disease in England is characterized by
behavioral changes, hyperexcitability, and agressiveness, it is very likely it would be
confused with rabies in the United Stales and not be diagnosed. Presently, brains from
cattle in the United States which are suspected of rabies infection are only tested with
anti-rabies virus antibody and are not examined histopathologically for lesions of
spongiform encephalopathy.
We are presently pursuing additional studies to further examine the possible
involvement of cattle in the epidemiology of TME. One of these is the backpassage of
our experimental bovine encephalopathy to mink. Because (here are as yet no agent-
specific proteins or nucleic acids identified for these transmissible neuropathogens, one
means of distinguishing them is by animal passage and selection of the biotype which
grows best in a particular host. This procedure has been used to separate hamster-
adapted and mink-udapted TME agents (Marsh and Hanson, 1979). The intracerebral
backpassage of the experimental bovine agent resulted in incubations of only four months
indicating no de-adaptation of the Stetsonville agent for mink after bovine passage.
Mink fed infected bovine brain remain normal after six months. It will be essential to
demonstrate oral transmission fiom bovine to mink it this proposed epidemiologic
association is to be confirmed.
ACKNOWLEDGEMENTS
These studies were supported by the College of Agricultural and Life Sciences,
University of Wisconsin-Madison and by a grant (85-CRCR-1-1812) from the United
States Department of Agriculture. The authors also wish to acknowledge the help and
encouragement of Robert Hanson who died during the course of these investigations.
REFERENCES
Burger, D. and Hartsough, G.R. 1965. Encephalopathy of mink. II. Experimental and
natural transmission. J. Infec. Dis. 115:393-399.
Hanson, R.P., Eckroade, R.3., Marsh, R.F., ZuRhein, C.M., Kanitz, C.L. and Gustatson,
D.P. 1971. Susceptibility of mink to sheep scrapie. Science 172:859-861.
Hansough, G.R. and Burger, D. 1965. Encephalopathy of mink. I. Epizoociologic and
clinical observations. 3. Infec. Dis. 115:387-392.
Marsh, R.F. and Hanson, R.P. 1969. Physical and chemical properties of the
transmissible mink encephalopathy agent. 3. ViroL 3:176-180.
Marsh, R.F. and Hanson, R.P. 1979. On the origin of transmissible mink
encephalopathy. In Hadlow, W.J. and Prusiner, S.P. (eds.) Slow transmissible
diseases of the nervous system. Vol. 1, Academic Press, New York, pp 451-460.
Marsh, R.F. and Hartsough, G.R. 1986. Is there a scrapie-like disease in cattle?
Proceedings of the Seventh Annual Western Conference for Food Animal Veterinary
Medicine. University of Arizona, pp 20.
Wells, G.A.H., Scott, A.C., Johnson, C.T., Cunning, R.F., Hancock, R.D., Jeffrey, M.,
Dawson, M. and Bradley, R. 1987. A novel progressive spongiform encephalopathy
in cattle. Vet. Rec. 121:419-420.
MARSH
http://www.bseinquiry.gov.uk/files/mb/m09/tab05.pdf
ANOTHER very questionable statement in the Alberta Perspective;
I am not convinced that the BSE issue is food related. Some 15% of CJD is familial
(genetic) and 85% is spontaneous, ...
FACTS ARE, the 85%+ of all CJD i.e. spontaneous/sporadic, simply means the route and source of the TSE agent is unknown, to date. the spontaneous TSE that Prusiner/Soto et al produced looked like NO field TSE to date, and the myth that the 85%+ sCJD is just that, a myth. IN fact, i wish to submit the following to dispute the UK/BSE/nvCJD only theory as a whole;
HUMAN and ANIMAL TSE Classifications i.e. mad cow
disease and the UKBSEnvCJD only theory
TSEs have been rampant in the USA for decades in many
species, and they all have been rendered and fed back
to animals for human/animal consumption. I propose that
the current diagnostic criteria for human TSEs only
enhances and helps the spreading of human TSE from the
continued belief of the UKBSEnvCJD only theory in 2005.
With all the science to date refuting it, to continue
to validate this myth, will only spread this TSE agent
through a multitude of potential routes and sources
i.e. consumption, surgical, blood, medical, cosmetics
etc. I propose as with Aguzzi, Asante, Collinge,
Caughey, Deslys, Dormont, Gibbs, Ironside, Manuelidis,
Marsh, et al and many more, that the world of TSE
Tranmissible Spongiform Encephalopathy is far from an
exact science, but there is enough proven science to
date that this myth should be put to rest once and for
all, and that we move forward with a new classification
for human and animal TSE that would properly identify
the infected species, the source species, and then the
route. This would further have to be broken down to
strain of species and then the route of transmission
would further have to be broken down. Accumulation and
Transmission are key to the threshold from subclinical
to clinical disease, and of that, I even believe that
physical and or blunt trauma may play a role of onset
of clinical symptoms in some cases, but key to all
this, is to stop the amplification and transmission of
this agent, the spreading of, no matter what strain.
BUT, to continue with this myth that the U.K. strain of
BSE one strain in cows, and the nv/v CJD, one strain in
humans, and that all the rest of human TSE is one
single strain i.e. sporadic CJD (when to date there are
6 different phenotypes of sCJD), and that no other
animal TSE transmits to humans, to continue with this
masquerade will only continue to spread, expose, and
kill, who knows how many more in the years and decades
to come. ONE was enough for me, My Mom, hvCJD, DOD
12/14/97 confirmed, which is nothing more than another
mans name added to CJD, like CJD itself, Jakob and
Creutzfeldt, or Gerstmann-Straussler-Scheinker
syndrome, just another CJD or human TSE, named after
another human. WE are only kidding ourselves with the
current diagnostic criteria for human and animal TSE,
especially differentiating between the nvCJD vs the
sporadic CJD strains and then the GSS strains and also
the FFI fatal familial insomnia strains or the ones
that mimics one or the other of those TSE? Tissue
infectivity and strain typing of the many variants of
the human and animal TSEs are paramount in all variants
of all TSE. There must be a proper classification that
will differentiate between all these human TSE in order
to do this. With the CDI and other more sensitive
testing coming about, I only hope that my proposal will
some day be taken seriously.
My name is Terry S. Singeltary Sr. and I am no
scientist, no doctor and have no PhDs, but have been
independently researching human and animal TSEs since
the death of my Mother to the Heidenhain Variant of
Creutzfeldt Jakob Disease on December 14, 1997
'confirmed'. ...TSS
Terry S. Singeltary Sr.
P.O. Box 42
Bacliff, Texas USA 77518
SOURCES
Full Text
Diagnosis and Reporting of Creutzfeldt-Jakob Disease
Singeltary, Sr et al.
JAMA.2001; 285: 733-734
http://jama.ama-assn.org/cgi/content/full/285/6/733?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=dignosing+and+reporting+creutzfeldt+jakob+disease&searchid=1048865596978_1528&stored_search=&FIRSTINDEX=0&journalcode=jama
Coexistence of multiple PrPSc types in individuals with
Creutzfeldt-Jakob disease
Magdalini Polymenidou, Katharina Stoeck, Markus
Glatzel, Martin Vey, Anne Bellon, and Adriano Aguzzi
Summary
Background The molecular typing of sporadic
Creutzfeldt-Jakob disease (CJD) is based on the size
and glycoform
ratio of protease-resistant prion protein (PrPSc), and
on PRNP haplotype. On digestion with proteinase K, type
1 and
type 2 PrPSc display unglycosylated core fragments of
21 kDa and 19 kDa, resulting from cleavage around amino
acids 82 and 97, respectively.
Methods We generated anti-PrP monoclonal antibodies to
epitopes immediately preceding the differential proteinase
K cleavage sites. These antibodies, which were
designated POM2 and POM12, recognise type 1, but not
type 2, PrPSc.
Findings We studied 114 brain samples from 70 patients
with sporadic CJD and three patients with variant CJD.
Every patient classified as CJD type 2, and all variant
CJD patients, showed POM2/POM12 reactivity in the
cerebellum and other PrPSc-rich brain areas, with a
typical PrPSc type 1 migration pattern.
Interpretation The regular coexistence of multiple
PrPSc types in patients with CJD casts doubts on the
validity of
electrophoretic PrPSc mobilities as surrogates for
prion strains, and questions the rational basis of
current CJD
classifications.
snip...
The above results set the existing CJD classifications
into debate and introduce interesting questions about
human CJD types. For example, do human prion types
exist in a dynamic equilibrium in the brains of affected
individuals? Do they coexist in most or even all CJD
cases? Is the biochemically identified PrPSc type simply
the dominant type, and not the only PrPSc species?
Published online October 31, 2005
http://neurology.thelancet.com
Detection of Type 1 Prion Protein in Variant
Creutzfeldt-Jakob Disease
Helen M. Yull,* Diane L. Ritchie,*
Jan P.M. Langeveld,? Fred G. van Zijderveld,?
Moira E. Bruce,? James W. Ironside,* and
Mark W. Head*
From the National CJD Surveillance Unit,* School of
Molecular
and Clinical Medicine, University of Edinburgh, Edinburgh,
United Kingdom; Central Institute for Animal Disease
Control
(CIDC)-Lelystad, ? Lelystad, The Netherlands; Institute
for Animal
Health, Neuropathogenesis Unit, ? Edinburgh, United Kingdom
Molecular typing of the abnormal form of the prion
protein (PrPSc) has come to be regarded as a powerful
tool in the investigation of the prion diseases. All
evidence
thus far presented indicates a single PrPSc molecular
type in variant Creutzfeldt-Jakob disease (termed
type 2B), presumably resulting from infection with a
single strain of the agent (bovine spongiform
encephalopathy).
Here we show for the first time that the PrPSc
that accumulates in the brain in variant Creutzfeldt-
Jakob disease also contains a minority type 1 component.
This minority type 1 PrPSc was found in all 21
cases of variant Creutzfeldt-Jakob disease tested,
irrespective
of brain region examined, and was also
present in the variant Creutzfeldt-Jakob disease tonsil.
The quantitative balance between PrPSc types was maintained
when variant Creutzfeldt-Jakob disease was
transmitted to wild-type mice and was also found in
bovine spongiform encephalopathy cattle brain, indicating
that the agent rather than the host specifies their
relative representation. These results indicate that PrPSc
molecular typing is based on quantitative rather than
qualitative phenomena and point to a complex relationship
between prion protein biochemistry, disease phenotype
and agent strain. (Am J Pathol 2006, 168:151-157;
DOI: 10.2353/ajpath.2006.050766)
snip...
Discussion
In the apparent absence of a foreign nucleic acid genome
associated with the agents responsible for transmissible
spongiform encephalopathies or prion diseases,
efforts to provide a molecular definition of agent strain
have focused on biochemical differences in the abnormal,
disease-associated form of the prion protein, termed
PrPSc. Differences in PrPSc conformation and glycosylation
have been proposed to underlie disease phenotype
and form the biochemical basis of agent strain. This
proposal has found support in the observation that the
major phenotypic subtypes of sCJD appear to correlate
with the presence of either type 1 or type 2 PrPSc in
combination with the presence of either methionine or
valine at codon 129 of the prion protein gene.2 Similarly,
the PrPSc type associated with vCJD correlates with the
presence of type 2 PrPSc and is distinct from that found in
sCJD because of a characteristically high occupancy of
both N-linked glycosylation sites (type 2B).6,11 The
means by which such conformational difference is detected
is somewhat indirect; relying on the action of proteases,
primarily proteinase K, to degrade the normal
Figure 6. Type 1 PrPSc is a stable minority component
of PrPSc from the vCJD
brain. Western blot analysis of PrP in a sample of
cerebral cortex from a
case
of vCJD during digestion with proteinase K is shown.
Time points assayed
are indicated in minutes (T0, 5, 10, 30, 60, 120, 180).
Duplicate blots were
probed with 3F4, which detects both type 1 and type 2
PrPSc, and with 12B2,
which detects type 1. The insert shows a shorter
exposure of the same time
course study from a separate experiment also probed
with 3F4. Both blots
included samples of cerebral cortex from a case of
sporadic CJD MM1 (Type
1) and molecular weight markers (Markers) indicate
weights in kd.
Figure 7. A minority type 1-like PrPSc is found in vCJD
tonsil, vCJD
transmitted
to mice and in BSE. Western blot analysis of PrPSc in a
concentrated
sample of tonsil from a case of vCJD (Tonsil), in a
concentrated brain
sample
of a wild-type mouse (C57BL) infected with vCJD and in
a sample of cattle
BSE brain (BSE) is shown. Tissue extracts were digested
with proteinase K.
Duplicate blots were probed with either 3F4 or 6H4,
both of which detect
type 1 and type 2 PrPSc, and with 12B2, which detects
type 1. The blots
included samples of cerebral cortex from a case of
sporadic CJD MM1 (Type
1) and molecular weight markers (Markers) indicate
weights in kd.
Type 1 PrPSc in Variant Creutzfeldt-Jakob Disease 155
AJP January 2006, Vol. 168, No. 1
cellular form of PrP and produce a protease-resistant
core fragment of PrPSc that differs in the extent of its
N-terminal truncation according to the original
conformation.
A complication has recently arisen with the finding that
both type 1 and type 2 can co-exist in the brains of
patients with sCJD.2,5-8 More recently this same phenomenon
has been demonstrated in patients with iatrogenically
acquired and familial forms of human prion disease.
9,10 The existence of this phenomenon is now
beyond doubt but its prevalence and its biological
significance
remain a matter of debate.
Conventional Western blot analysis using antibodies
that detect type 1 and type 2 PrPSc has severe quantitative
limitations for the co-detection of type 1 and type 2
PrPSc in individual samples, suggesting that the prevalence
of co-occurrence of the two types might be underestimated.
We have sought to circumvent this problem by
using an antibody that is type 1-specific and applied this
to the sole remaining human prion disease where the
phenomenon of mixed PrPSc types has not yet been
shown, namely vCJD.
These results show that even in vCJD where susceptible
individuals have been infected supposedly by a
single strain of agent, both PrPSc types co-exist: a
situation
reminiscent of that seen when similarly discriminant
antibodies were used to analyze experimental BSE in
sheep.14,17 In sporadic and familial CJD, individual
brains can show a wide range of relative amounts of the
two types in samples from different regions, but where
brains have been thoroughly investigated a predominant
type is usually evident.2,6,10 This differs from this
report
on vCJD, where type 1 is present in all samples
investigated
but always as a minor component that never
reaches a level at which it is detectable without a type
1-specific antibody. It would appear that the relative
balance
between type 1 and type 2 is controlled within
certain limits in the vCJD brain. A minority type-1-like
band is also detected by 12B2 in vCJD tonsil, in BSE
brain and in the brains of mice experimentally infected
with vCJD, suggesting that this balance of types is agent,
rather than host or tissue, specific. Interestingly the
"glycoform
signature" of the type 2 PrPSc found in vCJD (type
2B) is also seen in the type 1 PrPSc components, suggesting
that it could legitimately be termed type 1B.
PrPSc isotype analysis has proven to be extremely
useful in the differential diagnosis of CJD and is
likely to
continue to have a major role in the investigation of human
prion diseases. However, it is clear, on the basis of
these findings, that molecular typing has quantitative
limitations
and that any mechanistic explanation of prion
replication and the molecular basis of agent strain
variation
must accommodate the co-existence of multiple
prion protein conformers. Whether or not the different
conformers we describe here correlate in a simple and
direct way with agent strain remains to be determined. In
principle two interpretations present themselves: either
the two conformers can be produced by a single strain of
agent or vCJD (and, therefore, presumably BSE) results
from a mixture of strains, one of which generally
predominates.
Evidence for the isolation in mice of more than one
strain from individual isolates of BSE has been presented
previously.18,19
One practical consequence of our findings is that the
correct interpretation of transmission studies will depend
on a full examination of the balance of molecular types
present in the inoculum used to transmit disease, in
addition
to a thorough analysis of the molecular types that
arise in the recipients. Another consequence relates to
the diagnostic certainty of relying on PrPSc molecular
type alone when considering the possibility of BSE
infection
or secondary transmission in humans who have a
genotype other than methionine at codon 129 of the
PRNP gene. In this context it is interesting to note
that this
minority type 1B component resembles the type 5 PrPSc
described previously to characterize vCJD transmission
into certain humanized PRNP129VV transgenic mouse
models.12,20 This apparently abrupt change in molecular
phenotype might represent a selection process imposed
by this particular transgenic mouse model. Irrespective of
whether this proves to be the case, the results shown
here point to further complexities in the relationship
between
the physico-chemical properties of the prion protein,
human disease phenotype, and prion agent strain.
Acknowledgments
snip...
Type 1 PrPSc in Variant Creutzfeldt-Jakob Disease 157
AJP January 2006, Vol. 168, No. 1 ...TSS
http://ajp.amjpathol.org/cgi/content/abstract/168/1/151maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=prion&searchid=1136646133963_237&FIRSTINDEX=0&volume=168&issue=1&journalcode=amjpathol
Neuropathology and Applied Neurobiology
(2005),
31
, 565-579 doi: 10.1111/j.1365-2990.2005.00697.x
© 2005 Blackwell Publishing Ltd
565
Blackwell Science, LtdOxford, UKNANNeuropathology and
Applied Neurobiology0305-1846Blackwell Publishing Ltd, 2005
316565579
Review article
Phenotypic variability in human prion diseases
J. W. Ironside, D. L. Ritchie and M. W. Head
National Creutzfeldt-Jakob Disease Surveillance Unit,
Division of Pathology, University of Edinburgh,
Edinburgh, UK
J. W. Ironside, D. L. Ritchie and M. W. Head (2005)
Neuropathology and Applied Neurobiology
31,
565-579
Phenotypic variability in human prion diseases
Human prion diseases are rare neurodegenerative disorders
that can occur as sporadic, familial or acquired disorders.
Within each of these categories there is a wide range
of phenotypic variation that is not encountered in other
neurodegenerative disorders. The identification of the
prion protein and its key role in the pathogenesis of this
diverse group of diseases has allowed a fuller
understanding
of factors that influence disease phenotype. In particular,
the naturally occurring polymorphism at codon 129
in the prion protein gene has a major influence on the
disease
phenotype in sporadic, familial and acquired prion
diseases, although the underlying mechanisms remain
unclear. Recent technical advances have improved our
ability to study the isoforms of the abnormal prion protein
in the brain and in other tissues. This has lead to the
concept
of molecular strain typing, in which different isoforms
of the prion protein are proposed to correspond to
individual strains of the transmissible agent, each with
specific biological properties. In sporadic
Creutzfeldt-Jakob
disease there are at least six major combinations of codon
129 genotype and prion protein isotype, which appear to
relate to distinctive clinical subgroups of this disease.
However, these relationships are proving to be more complex
than first considered, particularly in cases with more
than a single prion protein isotype in the brain. Further
work is required to clarify these relationships and to
explain the mechanism of neuropathological targeting of
specific brain regions, which accounts for the diversity of
clinical features within human prion diseases.
© 2005 Blackwell Publishing Ltd, Neuropathology and
Applied Neurobiology, 31, 565-579
BSE prions propagate as either variant CJD-like or
sporadic CJD-like prion strains in transgenic mice
expressing human prion protein
The EMBO Journal Vol. 21 No. 23 pp. 6358±6366, 2002
Emmanuel A.Asante, Jacqueline M.Linehan,
Melanie Desbruslais, Susan Joiner,
Ian Gowland, Andrew L.Wood, Julie Welch,
Andrew F.Hill, Sarah E.Lloyd,
Jonathan D.F.Wadsworth and
John Collinge1
MRC Prion Unit and Department of Neurodegenerative Disease,
Institute of Neurology, University College, Queen Square,
London WC1N 3BG, UK
1Corresponding author
e-mail: j.collinge@prion.ucl.ac.uk
Variant Creutzfeldt±Jakob disease (vCJD) has been
recognized to date only in individuals homozygous for
methionine at PRNP codon 129. Here we show that
transgenic mice expressing human PrP methionine
129, inoculated with either bovine spongiform
encephalopathy (BSE) or variant CJD prions, may
develop the neuropathological and molecular phenotype
of vCJD, consistent with these diseases being
caused by the same prion strain. Surprisingly, however,
BSE transmission to these transgenic mice, in
addition to producing a vCJD-like phenotype, can also
result in a distinct molecular phenotype that is
indistinguishable
from that of sporadic CJD with PrPSc
type 2. These data suggest that more than one BSEderived
prion strain might infect humans; it is therefore
possible that some patients with a phenotype consistent
with sporadic CJD may have a disease arising
from BSE exposure.
snip...
These studies further strengthen the evidence that vCJD
is caused by a BSE-like prion strain. Also, remarkably, the
key neuropathological hallmark of vCJD, the presence of
abundant ¯orid PrP plaques, can be recapitulated on BSE
or vCJD transmission to these mice. However, the most
surprising aspect of the studies was the ®nding that an
alternate pattern of disease can be induced in 129MM
Tg35 mice from primary transmission of BSE, with a
molecular phenotype indistinguishable from that of a
subtype
of sporadic CJD. This ®nding has important potential
implications as it raises the possibility that some humans
infected with BSE prions may develop a clinical disease
indistinguishable from classical CJD associated with type 2
PrPSc. This is, in our experience, the commonest molecular
sub-type of sporadic CJD. In this regard, it is of interest
that the reported incidence of sporadic CJD has risen
in the
UK since the 1970s (Cousens et al., 1997). This has been
attributed to improved case ascertainment, particularly as
much of the rise is reported from elderly patients and
similar rises in incidence were noted in other European
countries without reported BSE (Will et al., 1998).
However, it is now clear that BSE is present in many
European countries, albeit at a much lower incidence than
was seen in the UK. While improved ascertainment is
likely to be a major factor in this rise, that some of
these
additional cases may be related to BSE exposure cannot be
ruled out. It is of interest in this regard that a 2-fold
increase in the reported incidence of sporadic CJD in 2001
has recently been reported for Switzerland, a country that
had the highest incidence of cattle BSE in continental
Europe between 1990 and 2002 (Glatzel et al., 2002). No
epidemiological case±control studies with strati®cation of
CJD cases by molecular sub-type have yet been reported.
It will be important to review the incidence of sporadic
CJD associated with PrPSc type 2 and other molecular
subtypes
in both BSE-affected and unaffected countries in the
light of these ®ndings. If human BSE prion infection can
result in propagation of type 2 PrPSc, it would be expected
that such cases would be indistinguishable on clinical,
pathological and molecular criteria from classical CJD. It
may also be expected that such prions would behave
biologically like those isolated from humans with sporadic
CJD with type 2 PrPSc. The transmission properties of
prions associated with type 2 PrPSc from BSE-inoculated
129MM Tg35 mice are being investigated by serial
passage.
We consider these data inconsistent with contamination
of some of the 129MM Tg35 mice with sporadic CJD
prions. These transmission studies were performed according
to rigorous biosafety protocols for preparation of
inocula and both the inoculation and care of mice, which
are all uniquely identi®ed by sub-cutaneous transponders.
However, crucially, the same BSE inocula have been used
on 129VV Tg152 and 129MM Tg45 mice, which are
highly sensitive to sporadic CJD but in which such
transmissions producing type 2 PrPSc were not observed.
Furthermore, in an independent experiment, separate
inbred lines of wild-type mice, which are highly resistant
to sporadic CJD prions, also propagated two distinctive
PrPSc types on challenge with either BSE or vCJD. No
evidence of spontaneous prion disease or PrPSc has been
seen in groups of uninoculated or mock-inoculated aged
129MM Tg35 mice.
While distinctive prion isolates have been derived from
BSE passage in mice previously (designated 301C and
301V), these, in contrast to the data presented here, are
propagated in mice expressing different prion proteins
(Bruce et al., 1994). It is unclear whether our ®ndings
indicate the existence of more than one prion strain in
individual cattle with BSE, with selection and preferential
replication of distinct strains by different hosts, or that
`mutation' of a unitary BSE strain occurs in some types of
host. Western blot analysis of single BSE isolates has not
shown evidence of the presence of a proportion of
monoglycosylated dominant PrPSc type in addition to the
diglycosylated dominant pattern (data not shown).
Extensive strain typing of large numbers of individual
BSE-infected cattle either by biological or molecular
methods has not been reported.
Presumably, the different genetic background of the
different inbred mouse lines is crucial in determining
which prion strain propagates on BSE inoculation. The
transgenic mice described here have a mixed genetic
background with contributions from FVB/N, C57BL/6 and
129Sv inbred lines; each mouse will therefore have a
different genetic background. This may explain the
differing response of individual 129MM Tg35 mice, and
the difference between 129MM Tg35 and 129MM Tg45
mice, which are, like all transgenic lines, populations
derived from single founders. Indeed, the consistent
distinctive strain propagation in FVB and C57BL/6 versus
SJL and RIIIS lines may allow mapping of genes relevant
to strain selection and propagation, and these studies
are in
progress.
That different prion strains can be consistently isolated
in different inbred mouse lines challenged with BSE
prions argues that other species exposed to BSE may
develop prion diseases that are not recognizable as being
caused by the BSE strain by either biological or molecular
strain typing methods. As with 129MM Tg35 mice, the
prions replicating in such transmissions may be
indistinguishable
from naturally occurring prion strains. It
remains of considerable concern whether BSE has transmitted
to, and is being maintained in, European sheep
¯ocks. Given the diversity of sheep breeds affected by
scrapie, it has to be considered that some sheep might have
become infected with BSE, but propagated a distinctive
strain type indistinguishable from those of natural sheep
scrapie. ...
The EMBO Journal Vol. 21 No. 23 pp. 6358±6366, 2002
6358 ãEuropean Molecular Biology Organization
http://embojournal.npgjournals.com/cgi/reprint/21/23/6358
J Neuropsychiatry Clin Neurosci 17:489-495, November 2005
doi: 10.1176/appi.neuropsych.17.4.489
© 2005 American Psychiatric Publishing, Inc.
Psychiatric Manifestations of Creutzfeldt-Jakob
Disease: A 25-Year Analysis
Christopher A. Wall, M.D., Teresa A. Rummans, M.D.,
Allen J. Aksamit, M.D.,
Lois E. Krahn, M.D. and V. Shane Pankratz, Ph.D.
Received April 20, 2004; revised September 9, 2004;
accepted September 13,
2004. From the Mayo Clinic, Department of Psychiatry
and Psychology,
Rochester, Minnesota; Mayo Clinic, Department of
Neurology, Rochester,
Minnesota. Address correspondence to Dr. Wall, Mayo
Clinic, Department of
Psychiatry and Psychology, Mayo Building-W11A, 200
First St., SW, Rochester,
MN 55905; wall.chris@mayo.edu (E-mail).
This study characterizes the type and timing of
psychiatric manifestations
in sporadic Creutzfeldt-Jakob disease (sCJD).
Historically, sCJD has been
characterized by prominent neurological symptoms, while
the variant form
(vCJD) is described as primarily psychiatric in
presentation and course: A
retrospective review of 126 sCJD patients evaluated at
the Mayo Clinic from
1976-2001 was conducted. Cases were reviewed for
symptoms of depression,
anxiety, psychosis, behavior dyscontrol, sleep
disturbances, and
neurological signs during the disease course. Eighty
percent of the cases
demonstrated psychiatric symptoms within the first 100
days of illness, with
26% occurring at presentation. The most commonly
reported symptoms in this
population included sleep disturbances, psychotic
symptoms, and depression.
Psychiatric manifestations are an early and prominent
feature of sporadic
CJD, often occurring prior to formal diagnosis.
snip...
CONCLUSIONS
Historically, psychiatric manifestations have been
described as a relatively
infrequent occurrence in the sporadic form of
creutzfeldt-Jakob disease.
However, our findings suggest otherwise. In this study,
a vast majority of
the cases were noted to have at least one psychiatric
symptom during the
course of illness, with nearly one-quarter occurring in
the prodromal or
presenting phase of the illness. After comparing the
frequency of
neuropsychiatric symptoms in sporadic CJD to studies
describing the variant
form of CJD, we found that there are fewer clinical
differences than
previously reported.5-7 While the age of patients
with vCJD presentation
is significantly younger and the course of illness is
longer, the type and
timing of psychiatric manifestations appear similar
between these two
diseases. ...snip...
http://neuro.psychiatryonline.org/cgi/content/abstract/17/4/489
Personal Communication
-------- Original Message --------
Subject: re-BSE prions propagate as
either variant CJD-like or sporadic CJD Date: Thu, 28
Nov 2002 10:23:43
-0000 From: "Asante, Emmanuel A" To:
"'flounder@wt.net'"
Dear Terry,
I have been asked by Professor Collinge to respond to
your request. I am
a Senior Scientist in the MRC Prion Unit and the lead
author on the
paper. I have attached a pdf copy of the paper for your
attention. Thank
you for your interest in the paper.
In respect of your first question, the simple answer
is, yes. As you
will find in the paper, we have managed to associate
the alternate
phenotype to type 2 PrPSc, the commonest sporadic CJD.
It is too early to be able to claim any further
sub-classification in
respect of Heidenhain variant CJD or Vicky Rimmer's
version. It will
take further studies, which are on-going, to establish
if there are
sub-types to our initial finding which we are now
reporting. The main
point of the paper is that, as well as leading to the
expected new
variant CJD phenotype, BSE transmission to the
129-methionine genotype
can lead to an alternate phenotype which is
indistinguishable from type
2 PrPSc.
I hope reading the paper will enlighten you more on the
subject. If I
can be of any further assistance please to not hesitate
to ask. Best wishes.
Emmanuel Asante
<> ____________________________________
Dr. Emmanuel A Asante MRC Prion Unit & Neurogenetics
Dept. Imperial
College School of Medicine (St. Mary's) Norfolk Place,
LONDON W2 1PG
Tel: +44 (0)20 7594 3794 Fax: +44 (0)20 7706 3272 email:
e.asante@ic.ac.uk (until 9/12/02)
New e-mail: e.asante@prion.ucl.ac.uk (active from now)
____________________________________
Human Prion Protein with
Valine 129 Prevents Expression
of Variant CJD Phenotype
Jonathan D. F. Wadsworth, Emmanuel A. Asante,
Melanie Desbruslais, Jacqueline M. Linehan, Susan Joiner,
Ian Gowland, Julie Welch, Lisa Stone, Sarah E. Lloyd,
Andrew F. Hill,* Sebastian Brandner, John Collinge.
Variant Creutzfeldt-Jakob disease (vCJD) is a unique
and highly distinctive
clinicopathological and molecular phenotype of human
prion disease
associated with infection with bovine spongiform
encephalopathy (BSE)-like
prions. Here, we found that generation of this
phenotype in transgenic mice
required expression of human prion protein (PrP) with
methionine 129.
Expression of human PrP with valine 129 resulted in a
distinct phenotype and,
remarkably, persistence of a barrier to transmission of
BSE-derived prions on
subpassage. Polymorphic residue 129 of human PrP
dictated propagation of
distinct prion strains after BSE prion infection. Thus,
primary and secondary
human infection with BSE-derived prions may result in
sporadic CJD-like or
novel phenotypes in addition to vCJD, depending on the
genotype of the prion
source and the recipient.
snip...
3 DECEMBER 2004 VOL 306 SCIENCE
http://www.sciencemag.org
Characterization of two distinct prion strains
derived from bovine spongiform encephalopathy
transmissions to inbred mice
Sarah E. Lloyd, Jacqueline M. Linehan, Melanie Desbruslais,
Susan Joiner, Jennifer Buckell, Sebastian Brandner,
Jonathan D. F. Wadsworth and John Collinge
Correspondence
John Collinge
j.collinge@prion.ucl.ac.uk
MRC Prion Unit and Department of Neurodegenerative
Disease, Institute of Neurology,
University College, London WC1N 3BG, UK
Received 9 December 2003
Accepted 27 April 2004
Distinct prion strains can be distinguished by
differences in incubation period, neuropathology
and biochemical properties of disease-associated prion
protein (PrPSc) in inoculated mice.
Reliable comparisons of mouse prion strain properties
can only be achieved after passage in
genetically identical mice, as host prion protein
sequence and genetic background are known
to modulate prion disease phenotypes. While multiple
prion strains have been identified in
sheep scrapie and Creutzfeldt-Jakob disease, bovine
spongiform encephalopathy (BSE) is
thought to be caused by a single prion strain. Primary
passage of BSE prions to different lines
of inbred mice resulted in the propagation of two
distinct PrPSc types, suggesting that two
prion strains may have been isolated. To investigate
this further, these isolates were
subpassaged in a single line of inbred mice (SJL) and
it was confirmed that two distinct prion
strains had been identified. MRC1 was characterized by
a short incubation time (110±3 days),
a mono-glycosylated-dominant PrPSc type and a
generalized diffuse pattern of PrP-immunoreactive
deposits, while MRC2 displayed a much longer incubation
time (155±1 days),
a di-glycosylated-dominant PrPSc type and a distinct
pattern of PrP-immunoreactive deposits
and neuronal loss. These data indicate a crucial
involvement of the host genome in modulating
prion strain selection and propagation in mice. It is
possible that multiple disease phenotypes
may also be possible in BSE prion infection in humans
and other animals.
snip...
Journal of General Virology (2004), 85, 2471-2478 DOI
10.1099/vir.0.79889-0
http://vir.sgmjournals.org/cgi/content/abstract/85/8/2471
Medical Sciences
Identification of a second bovine amyloidotic
spongiform encephalopathy: Molecular similarities with
sporadic Creutzfeldt-Jakob disease
Cristina Casalone *, Gianluigi Zanusso , Pierluigi
Acutis *, Sergio Ferrari , Lorenzo Capucci , Fabrizio
Tagliavini ¶, Salvatore Monaco ||, and Maria Caramelli *
*Centro di Referenza Nazionale per le Encefalopatie
Animali, Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta, Via Bologna, 148,
10195 Turin, Italy; Department of Neurological and
Visual Science, Section of Clinical Neurology,
Policlinico G.B. Rossi, Piazzale L.A. Scuro, 10, 37134
Verona, Italy; Istituto Zooprofilattico Sperimentale
della Lombardia ed Emilia Romagna, Via Bianchi, 9,
25124 Brescia, Italy; and ¶Istituto Nazionale
Neurologico "Carlo Besta," Via Celoria 11, 20133 Milan,
Italy
Edited by Stanley B. Prusiner, University of
California, San Francisco, CA, and approved December
23, 2003 (received for review September 9, 2003)
Transmissible spongiform encephalopathies (TSEs), or
prion diseases, are mammalian neurodegenerative
disorders characterized by a posttranslational
conversion and brain accumulation of an insoluble,
protease-resistant isoform (PrPSc) of the host-encoded
cellular prion protein (PrPC). Human and animal TSE
agents exist as different phenotypes that can be
biochemically differentiated on the basis of the
molecular mass of the protease-resistant PrPSc
fragments and the degree of glycosylation.
Epidemiological, molecular, and transmission studies
strongly suggest that the single strain of agent
responsible for bovine spongiform encephalopathy (BSE)
has infected humans, causing variant Creutzfeldt-Jakob
disease. The unprecedented biological properties of the
BSE agent, which circumvents the so-called "species
barrier" between cattle and humans and adapts to
different mammalian species, has raised considerable
concern for human health. To date, it is unknown
whether more than one strain might be responsible for
cattle TSE or whether the BSE agent undergoes
phenotypic variation after natural transmission. Here
we provide evidence of a second cattle TSE. The
disorder was pathologically characterized by the
presence of PrP-immunopositive amyloid plaques, as
opposed to the lack of amyloid deposition in typical
BSE cases, and by a different pattern of regional
distribution and topology of brain PrPSc accumulation.
In addition, Western blot analysis showed a PrPSc type
with predominance of the low molecular mass glycoform
and a protease-resistant fragment of lower molecular
mass than BSE-PrPSc. Strikingly, the molecular
signature of this previously undescribed bovine PrPSc
was similar to that encountered in a distinct subtype
of sporadic Creutzfeldt-Jakob disease.
--------------------------------------------------------------------------------
C.C. and G.Z. contributed equally to this work.
||To whom correspondence should be addressed.
E-mail: salvatore.monaco@mail.univr.it .
www.pnas.org/cgi/doi/10.1073/pnas.0305777101
snip...
Phenotypic Similarities Between BASE and sCJD. The
transmissibility
of CJD brains was initially demonstrated in primates
(27), and
classification of atypical cases as CJD was based on
this property
(28). To date, no systematic studies of strain typing
in sCJD have
been provided, and classification of different subtypes
is based
on clinical, neuropathological, and molecular features
(the polymorphic
PRNP codon 129 and the PrPSc glycotype) (8, 9, 15, 19).
The importance of molecular PrPSc characterization in
assessing
the identity of TSE strains is underscored by several
studies,
showing that the stability of given disease-specific
PrPSc types is
maintained upon experimental propagation of sCJD, familial
CJD, and vCJD isolates in transgenic PrP-humanized mice (8,
29). Similarly, biochemical properties of BSE- and
vCJDassociated
PrPSc molecules remain stable after passage to mice
expressing bovine PrP (30). Recently, however, it has been
reported that PrP-humanized mice inoculated with BSE
tissues
may also propagate a distinctive PrPSc type, with a
''monoglycosylated-
dominant'' pattern and electrophoretic mobility of the
unglycosylated fragment slower than that of vCJD and
BSE (31).
Strikingly, this PrPSc type shares its molecular
properties with the
a PrPSc molecule found in classical sCJD. This
observation is at
variance with the PrPSc type found in MV2 sCJD cases and in
cattle BASE, showing a monoglycosylated-dominant
pattern but
faster electrophoretic mobility of the
protease-resistant fragment
as compared with BSE. In addition to molecular properties
of PrPSc, BASE and MV2 sCJD share a distinctive pattern of
intracerebral PrP deposition, which occurs as
plaque-like and
amyloid-kuru plaques. Differences were, however,
observed in
the regional distribution of PrPSc. While inMV2 sCJD
cases the
largest amounts of PrPSc were detected in the cerebellum,
brainstem, and striatum, in cattle BASE these areas
were less
involved and the highest levels of PrPSc were recovered
from the
thalamus and olfactory regions.
In conclusion, decoding the biochemical PrPSc signature of
individual human and animal TSE strains may allow the
identification
of potential risk factors for human disorders with
unknown etiology, such as sCJD. However, although BASE and
sCJD share several characteristics, caution is dictated
in assessing
a link between conditions affecting two different mammalian
species, based on convergent biochemical properties of
diseaseassociated
PrPSc types. Strains of TSE agents may be better
characterized upon passage to transgenic mice. In the
interim
until this is accomplished, our present findings
suggest a strict
epidemiological surveillance of cattle TSE and sCJD
based on
molecular criteria.
http://www.pnas.org/cgi/reprint/0305777101v1
Published online before print March 20, 2001,
10.1073/pnas.041490898
Neurobiology
Adaptation of the bovine spongiform encephalopathy
agent to primates and comparison with Creutzfeldt-
Jakob disease: Implications for human health
Corinne Ida Lasmézas*,, Jean-Guy Fournier*, Virginie
Nouvel*, Hermann Boe*, Domíníque Marcé*, François
Lamoury*, Nicolas Kopp, Jean-Jacques Hauw§, James
Ironside¶, Moira Bruce, Dominique Dormont*, and
Jean-Philippe Deslys*
* Commissariat à l'Energie Atomique, Service de
Neurovirologie, Direction des Sciences du
Vivant/Département de Recherche Medicale, Centre de
Recherches du Service de Santé des Armées 60-68, Avenue
du Général Leclerc, BP 6, 92 265 Fontenay-aux-Roses
Cedex, France; Hôpital Neurologique Pierre Wertheimer,
59, Boulevard Pinel, 69003 Lyon, France; § Laboratoire
de Neuropathologie, Hôpital de la Salpêtrière, 83,
Boulevard de l'Hôpital, 75013 Paris, France; ¶
Creutzfeldt-Jakob Disease Surveillance Unit, Western
General Hospital, Crewe Road, Edinburgh EH4 2XU, United
Kingdom; and Institute for Animal Health,
Neuropathogenesis Unit, West Mains Road, Edinburgh EH9
3JF, United Kingdom
Edited by D. Carleton Gajdusek, Centre National de la
Recherche Scientifique, Gif-sur-Yvette, France, and
approved December 7, 2000 (received for review October
16, 2000)
Abstract
There is substantial scientific evidence to support the
notion that bovine spongiform encephalopathy (BSE) has
contaminated human beings, causing variant
Creutzfeldt-Jakob disease (vCJD). This disease has
raised concerns about the possibility of an iatrogenic
secondary transmission to humans, because the
biological properties of the primate-adapted BSE agent
are unknown. We show that (i) BSE can be transmitted
from primate to primate by intravenous route in 25
months, and (ii) an iatrogenic transmission of vCJD to
humans could be readily recognized pathologically,
whether it occurs by the central or peripheral route.
Strain typing in mice demonstrates that the BSE agent
adapts to macaques in the same way as it does to humans
and confirms that the BSE agent is responsible for vCJD
not only in the United Kingdom but also in France. The
agent responsible for French iatrogenic growth
hormone-linked CJD taken as a control is very different
from vCJD but is similar to that found in one case of
sporadic CJD and one sheep scrapie isolate. These data
will be key in identifying the origin of human cases of
prion disease, including accidental vCJD transmission,
and could provide bases for vCJD risk assessment.
snip...
Characterization of the CJD and Scrapie Strains.
Controls were set up by transmitting one French and one
U.S. scrapie isolate from ruminants as well as French
sCJD and iCJD cases from humans. None of these revealed
a lesion profile or transmission characteristics
similar or close to those of BSE or vCJD, respectively,
thus extending to the present French scrapie isolate
the previous observation that the BSE agent was
different from all known natural scrapie strains (4, 24).
The lesion profiles of sCJD and iCJD differed only
slightly in severity of the lesions, but not in shape
of the profile, revealing the identity of the causative
agents. One of us reported the absence of similarity
between sCJD (six cases) and U.K. scrapie (eight cases)
in transmission characteristics in mice (4). Herein, we
made the striking observation that the French natural
scrapie strain (but not the U.S. scrapie strain) has
the same lesion profile and transmission times in
C57BL/6 mice as do the two human TSE strains studied.
This strain "affiliation" was confirmed biochemically.
There is no epidemiological evidence for a link between
sheep scrapie and the occurrence of CJD in humans (25).
However, such a link, if it is not a general rule,
would be extremely difficult to establish because of
the very low incidence of CJD as well as the existence
of different isolates in humans and multiple strains in
scrapie. Moreover, scrapie is transmissible to nonhuman
primates (26). Thus, there is still a possibility that
in some instances TSE strains infecting humans do share
a common origin with scrapie, as pointed out by our
findings.
snip...
http://www.pnas.org/cgi/content/full/041490898v1
1: J Infect Dis 1980 Aug;142(2):205-8
Oral transmission of kuru, Creutzfeldt-Jakob disease,
and scrapie to nonhuman primates.
Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.
Kuru and Creutzfeldt-Jakob disease of humans and
scrapie disease of sheep and goats were transmitted to
squirrel monkeys (Saimiri sciureus) that were exposed
to the infectious agents only by their nonforced
consumption of known infectious tissues. The
asymptomatic incubation period in the one monkey
exposed to the virus of kuru was 36 months; that in the
two monkeys exposed to the virus of Creutzfeldt-Jakob
disease was 23 and 27 months, respectively; and that in
the two monkeys exposed to the virus of scrapie was 25
and 32 months, respectively. Careful physical
examination of the buccal cavities of all of the
monkeys failed to reveal signs or oral lesions. One
additional monkey similarly exposed to kuru has
remained asymptomatic during the 39 months that it has
been under observation.
PMID: 6997404
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6997404&dopt=Abstract
NOTES
Interspecies Transmission of Chronic Wasting Disease
Prions to
Squirrel Monkeys (Saimiri sciureus)
Richard F. Marsh,1? Anthony E. Kincaid,2 Richard A.
Bessen,3 and Jason C. Bartz4*
Department of Animal Health and Biomedical Sciences,
University of Wisconsin, Madison 537061; Department of
Physical Therapy2 and Department of Medical
Microbiology and Immunology,4 Creighton University, Omaha,
Nebraska 68178; and Department of Veterinary Molecular
Biology, Montana
State University, Bozeman, Montana 597183
Received 3 May 2005/Accepted 10 August 2005
Chronic wasting disease (CWD) is an emerging prion
disease of deer and elk. The risk of CWD transmission
to humans following exposure to CWD-infected tissues is
unknown. To assess the susceptibility of nonhuman
primates to CWD, two squirrel monkeys were inoculated
with brain tissue from a CWD-infected mule deer. The
CWD-inoculated squirrel monkeys developed a progressive
neurodegenerative disease and were euthanized at
31 and 34 months postinfection. Brain tissue from the
CWD-infected squirrel monkeys contained the abnormal
isoform of the prion protein, PrP-res, and displayed
spongiform degeneration. This is the first reported
transmission of CWD to primates.
snip...
JOURNAL OF VIROLOGY, Nov. 2005, p. 13794-13796 Vol.
79, No. 21
0022-538X/05/$08.00!0
doi:10.1128/JVI.79.21.13794-13796.2005
Copyright © 2005, American Society for Microbiology.
All Rights Reserved.
=============================================
Research Project: Transmission, Differentiation, and Pathobiology of Transmissible Spongiform Encephalopathies
Location: Virus and Prion Diseases of Livestock
Title: Experimental Second Passage of Chronic Wasting Disease (Cwd-Mule Deer) Agent to Cattle
Authors
Hamir, Amirali
Kunkle, Robert - bob
Miller, Janice - ARS RETIRED
Greenlee, Justin
Richt, Juergen
Submitted to: Journal Of Comparative Pathology
Publication Acceptance Date: July 25, 2005
Publication Date: N/A
Interpretive Summary: To compare the findings of experimental first and second passage of chronic wasting disease (CWD) in cattle, 6 calves were inoculated into the brain with CWD-mule deer agent previously (first) passaged in cattle. Two other uninoculated calves served as controls. Beginning 10-12 months post inoculation (PI), all inoculates lost appetite and weight. Five animals subsequently developed clinical signs of central nervous system (CNS) abnormality. By 16.5 months PI, all cattle had been euthanized because of poor prognosis. None of the animals showed microscopic lesions of spongiform encephalopathy (SE) but the CWD agent was detected in their CNS tissues by 2 laboratory techniques (IHC and WB). These findings demonstrate that inoculated cattle amplify CWD agent but also develop clinical CNS signs without manifestation of microscopic lesions of SE. This situation has also been shown to occur following inoculation of cattle with another TSE agent, namely, sheep scrapie. The current study confirms previous work that indicates that the diagnostic tests currently used for confirmation of bovine spongiform encephalopathy (BSE) in the U.S. would detect CWD in cattle, should it occur naturally. Furthermore, it raises the possibility of distinguishing CWD from BSE in cattle due to the absence of microscopic lesions and a unique multifocal distribution of PrPres, as demonstrated by IHC, which in this study, appears to be more sensitive than the WB.
Technical Abstract: To compare clinicopathological findings of first and second passage of chronic wasting disease (CWD) in cattle, a group of calves (n=6) were intracerebrally inoculated with CWD-mule deer agent previously (first) passaged in cattle. Two other uninoculated calves served as controls. Beginning 10-12 months post inoculation (PI), all inoculates lost appetite and lost weight. Five animals subsequently developed clinical signs of central nervous system (CNS) abnormality. By 16.5 months PI, all cattle had been euthanized because of poor prognosis. None of the animals showed microscopic lesions of spongiform encephalopathy (SE) but PrPres was detected in their CNS tissues by immunohistochemistry (IHC) and Western blot (WB) techniques. These findings demonstrate that intracerebrally inoculated cattle not only amplify CWD PrPres but also develop clinical CNS signs without manifestation of morphologic lesions of SE. This situation has also been shown to occur following inoculation of cattle with another TSE agent, scrapie. The current study confirms previous work that indicates the diagnostic techniques currently used for confirmation of bovine spongiform encephalopathy (BSE) in the U.S. would detect CWD in cattle, should it occur naturally. Furthermore, it raises the possibility of distinguishing CWD from BSE in cattle due to the absence of neuropathologic lesions and a unique multifocal distribution of PrPres, as demonstrated by IHC, which in this study, appears to be more sensitive than the WB.
http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=178318
======================================================
The EMBO Journal, Vol. 19, No. 17 pp. 4425-4430, 2000
© European Molecular Biology Organization
Evidence of a molecular barrier limiting
susceptibility of humans, cattle and sheep to
chronic wasting disease
G.J. Raymond1, A. Bossers2, L.D. Raymond1, K.I. O?Rourke3,
L.E. McHolland4, P.K. Bryant III4, M.W. Miller5, E.S.
Williams6, M.
Smits2
and B. Caughey1,7
1NIAID/NIH Rocky Mountain Laboratories, Hamilton, MT
59840,
3USDA/ARS/ADRU, Pullman, WA 99164-7030, 4USDA/ARS/ABADRL,
Laramie, WY 82071, 5Colorado Division of Wildlife,
Wildlife Research
Center, Fort Collins, CO 80526-2097, 6Department of
Veterinary Sciences,
University of Wyoming, Laramie, WY 82070, USA and
2ID-Lelystad,
Institute for Animal Science and Health, Lelystad, The
Netherlands
7Corresponding author e-mail: bcaughey@nih.gov Received
June 7, 2000;
revised July 3, 2000; accepted July 5, 2000.
Abstract
Chronic wasting disease (CWD) is a transmissible
spongiform encephalopathy (TSE) of deer and elk,
and little is known about its transmissibility to other
species. An important factor controlling
interspecies TSE susceptibility is prion protein (PrP)
homology between the source and recipient
species/genotypes. Furthermore, the efficiency with which
the protease-resistant PrP (PrP-res) of one
species induces the in vitro conversion of the normal PrP
(PrP-sen) of another species to the
protease-resistant state correlates with the cross-species
transmissibility of TSE agents. Here we
show that the CWD-associated PrP-res (PrPCWD) of cervids
readily induces the conversion of recombinant cervid
PrP-sen
molecules to the protease-resistant state in accordance
with the known transmissibility of CWD between cervids.
In contrast,
PrPCWD-induced conversions of human and bovine PrP-sen
were
much less efficient, and conversion of ovine PrP-sen was
intermediate. These results demonstrate a barrier at the
molecular level that should limit the susceptibility of
these non-cervid
species to CWD.
snip...
Clearly, it is premature to draw firm conclusions about
CWD
passing naturally into humans, cattle and sheep, but
the present
results suggest that CWD transmissions to humans would
be as
limited by PrP incompatibility as transmissions of BSE
or sheep
scrapie to humans. Although there is no evidence that
sheep
scrapie has affected humans, it is likely that BSE has
caused variant
CJD in 74 people (definite and probable variant CJD
cases to
date according to the UK CJD Surveillance Unit). Given the
presumably large number of people exposed to BSE
infectivity,
the susceptibility of humans may still be very low
compared with
cattle, which would be consistent with the relatively
inefficient
conversion of human PrP-sen by PrPBSE. Nonetheless, since
humans have apparently been infected by BSE, it would
seem prudent
to take reasonable measures to limit exposure of humans
(as well as sheep and cattle) to CWD infectivity as has
been
recommended for other animal TSEs.
snip...
http://www.emboj.org/current.shtml
Neurology 1999;52:1757
© 1999 American Academy of Neurology
--------------------------------------------------------------------------------
Expedited Publication
A subtype of sporadic prion disease mimicking fatal
familial insomnia
P. Parchi, MD, S. Capellari, MD, S. Chin, MD, PhD, H.
B. Schwarz, MD, N. P. Schecter, MD, J. D. Butts, MD, P.
Hudkins, MD, D. K. Burns MD, J. M. Powers, MD and P.
Gambetti, MD
http://www.neurology.org/cgi/content/abstract/52/9/1757
Transfusion
Volume 43 Issue 12 Page 1687 - December 2003
doi:10.1046/j.0041-1132.2003.00586.x
Similar levels of infectivity in the blood of mice
infected with
human-derived vCJD and GSS strains of transmissible
spongiform
encephalopathy
Larisa Cervenakova, Oksana Yakovleva, Carroll McKenzie,
Svetlana
Kolchinsky, Lisa McShane, William N. Drohan, and Paul Brown
BACKGROUND:
The possible transmission of variant CJD (vCJD) through
blood
transfusion or use of plasma-derived products prompted
this study
comparing infectivity in murine models of vCJD and
Gerstmann-Sträussler-Scheinker (GSS) disease, a
non-vCJD form of
transmissible spongiform encephalopathy (TSE).
STUDY DESIGN AND METHODS:
RIII/Fa/Dk (RIII) or Swiss-Webster (Swiss) mice were
inoculated
intracerebrally (IC) with mouse-adapted strains of vCJD
or GSS
(Fukuoka-1) of similar infectivity. Groups of RIII mice
were euthanized
17 weeks after inoculation (during the incubation
period), and another
23 weeks after inoculation (when symptomatic). Blood
was collected,
separated into components, and inoculated into groups
of healthy mice;
brains and spleens from all mice were harvested and
tested for the
presence of PrPres by Western blot using 6H4 MoAb.
RESULTS:
Levels of 20-30 infectious doses per mL were present in
buffy coat and
plasma during both the incubation and symptomatic
stages of disease; PLT
pellet infectivity was lower (10 ID/mL) and RBCs were
not infectious.
The disease was transmitted more efficiently by IV than
IC inoculation
of plasma, but there was no difference observed with
inoculation of
buffy coat. The incubation period was shorter after IC
inoculation of
GSS- than vCJD-brain inocula. The amount of PrPres in
spleens was
similar for both TSE agents, but was slightly lower in
brains of vCJD
than GSS mice.
CONCLUSION:
Infectivity was detected in blood components of mice
infected with a
human-derived strain of vCJD during both the
preclinical and clinical
phases of disease in a similarly low range of
concentrations as in mice
infected with a human-derived nonvariant strain (GSS,
Fukuoka-1). Other
measures of virulence, including brain infectivity
titers, incubation
periods, and the accumulation of PrPres in spleens and
brains, were also
comparable in both experimental models.
http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0041-1132&date=2003&volume=43&issue=12&spage=1687
http://www.blackwell-synergy.com/doi/abs/10.1046/j.0041-1132.2003.00586.x
SEAC
POSITION STATEMENT
EARLY PHASE OF vCJD INFECTION IN BLOOD TRANSFUSION
RECIPIENTS
http://www.seac.gov.uk/pdf/cjd.pdf
SEAC
Summary of SEAC's discussion on the second presumed
case of blood
transfusion-associated infection with vCJD
http://www.seac.gov.uk/statements/statement070804.pdf
Transmission of Creutzfeldt-Jakob Disease from Blood
and Urine Into Mice
The Lancet, November 9, 1985
Sir,--Professor Manuelidis and his colleagues (Oct 19,
p896) report
transmission to animals of Creutzfeldt-Jakob disease
(CJD) from the
buffy coat from two patients. We also transmitted the
disease from
whole blood samples of a patient (and of mice) infected
with CJD.1
Brain, Cornea, and urine from this patient were also
infectious, and
the clinicopathological findings2 are summarised as
follows.
A 70-year-old man was noted to have a slowing of speech
and writing
and some disorientation, all of which progressed
rapidly. Decorticate
rigidity, forced grasping, positive snout reflex, and
myoclonus
appeared within 2 months. Electroencephalogram revealed
typical
periodic synchronous discharge, and he died of
pneumonia and upper
gastrointestinal haemorrhage, about 3 months after
onset of the
symptoms. The Brain weighed 1290g and showed severe
histological
changes diagnostic of CJD, including spongiform change,
loss of
nerve cells, and diffuse proliferation of astrocytes.
There were no
inflammatory cells, microglia, neurofibrillary tangles,
and
amyloid plaques, although virus-like particles were
detected by
electron microscopy.
Results of innoculation in Mice
Inocula NO* Incubation period (days)+
Brain 7/10 (4) 789 (+ or - 112)
Cornea 1/6 (0) 1037
Blood 2/13 (0) 1080 (+ or - 69)
Urine 5/10 (1) 880 (+ or - 55)
CSF 0/10
* Number of mice with CJD change/number examined
histologically.
Number with amyloid plaques shown in parentheses.
+ means + or - SD
Samples were taken aseptically at necropsy. 10% crude
homogenates
of brain and cornea in saline, whole blood (after
crushing a clot),
and untreated CSF and urine were innoculated
intracerebrally into
CF1 strain mice (20 ul per animal). Some mice showed
emaciation,
bradykinesia, rigidity of the body and tail, and
sometimes tremor
after long incubation periods. Tissues obtained after
the animal
died (or was killed) were studied histologically
(table). Animals
infected by various inocula showed common pathological
changes,
consisting of severe spongiform changes, glial
proliferation, and
a moderate loss of nerve cells. A few mice inoculated
with brain
tissue or urine had the same amyloid plaques found in
patients and
animals with CJD.3
In our long-term experiments, inoculating materials
taken from
twenty patients with CJD or
Gerstmann-Straussler-Scheinker's
disease (GSS) into rodents, positive results were
obtained in
seventeen cases, including this patient. Brain tissue
transmitted
the disease most frequently within the shortes
incubation period,
except for one case where the lymph node was the most
infectious.
Transmission through the cornea has been noted in man4
and in
guineapigs.5 Whole blood samples taken from three
patients were
inoculated and a positive transmission occured only in
the case
recorded here. Mouse-to-mouse transmission through blood
inoculation was successful after a mean incubation
period of 365
days.1 Transmission through urine was positive in this
patient
only, and negative in one other patient and in many
infected animals.
Transmission through the CSF from eight patients was
negative, yet
transmission via the CSF of infected rats was positive.1
As viraemia has been proved in guineapigs,6 mice,1,7
and lately
in patients with CJD, blood for transfusion or blood
products for
medical use must be tested for unconventional
pathogens. For this
purpose, we inoculated blood products inot rodents.8
The CJD
pathogen was not found in the products examined.
However, this
approach takes too long to be of practical value. More
efficient
methods must be developed to detect pathogens and to
eliminate
them from blood. One proposal9 is to apply membrane
filtration to
the pruification protocol of human growth hormone
suspected of
being contaminated with CJD. Similar methods are needed
for blood
contamination.
Department of Neuropathology,
Neurological Institute,
Faculty of Medicine,
Kyushu University,
Fukuoka812, Japan
JUN TATEISHI
1. Tateishi J, Sato Y, Kaga M. Doi H, Ohta M.
Experimental transmission
of human subacute spongiform encephalopathy to small
rodents 1: Clinical and histological observations.
Acta Neuropathol (Berl) 1980; 51: 127.
2. Shibayama Y, Sakaguchi Y, Nakata K, et al,
Creutzfeldt-Jakob
disease with demonstration of virus-like particles.
Acta pathol Jpn 1982;32: 695.
3. Tateishi J, Nagara H, Hikita K, Sato Y. Amyloid
plaques in the
brains of mice with Creutzfeldt-Jakob disease.
Ann Neurol 1984; 15: 278.
4. Duffy P, Wolf J, Colings G, DeVoe AG, Streeten B,
Cowen D.
Possible person-to-person transmission of
Creutzfeldt-Jakob disease.
N Engl J Med 1974; 290: 692.
5. Manuelidis EE, Angelo JN, Gorgacz EJ, Kim JH,
Manuelidis L.
Experimental Creutzfeldt-Jakob disease transmitted via
the eye
with infected cornea. N Engl J Med 1977; 296: 1334.
6. Manuelidis EE, Gorgacz EJ, Manuelidis L. Viremia in
experimental
Creutzfeldt-Jakob disease. Science 1978: 200: 1069.
7. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC.
Creutzfeldt-Jakob disease in mice. Persistent viremiam and
preferential replication of virus in low-density
lymphocytes.
Infect Immun 1983; 41: 154.
8. Tateishi J, Tsuji S. Unconventional pathogens
causing spongiform
encephalopathis absent in blood products. J Med Virol
1985; 15: 11.
9. Tateishi J, Kitamoto T, Hiratani H.
Creutzfeldt-Jakob disease
pathogen in growth hormone preparations is eliminatable.
Lancet (in press).
http://www.thelancet.com/
LANCET INFECTIOUS DISEASE JOURNAL
Volume 3, Number 8 01 August 2003
Newsdesk
Tracking spongiform encephalopathies in North America
Xavier Bosch
My name is Terry S Singeltary Sr, and I live in
Bacliff, Texas. I lost
my mom to hvCJD (Heidenhain variant CJD) and have been
searching for
answers ever since. What I have found is that we have
not been told the
truth. CWD in deer and elk is a small portion of a much
bigger problem.
49-year-old Singeltary is one of a number of people who
have remained
largely unsatisfied after being told that a close
relative died from a
rapidly progressive dementia compatible with spontaneous
Creutzfeldt-Jakob disease (CJD). So he decided to
gather hundreds of
documents on transmissible spongiform encephalopathies
(TSE) and
realised that if Britons could get variant CJD from
bovine spongiform
encephalopathy (BSE), Americans might get a similar
disorder from
chronic wasting disease (CWD) the relative of mad cow
disease seen among
deer and elk in the USA. Although his feverish search
did not lead him
to the smoking gun linking CWD to a similar disease in
North American
people, it did uncover a largely disappointing situation.
Singeltary was greatly demoralised at the few attempts
to monitor the
occurrence of CJD and CWD in the USA. Only a few
states have made CJD
reportable. Human and animal TSEs should be reportable
nationwide and
internationally, he complained in a letter to the
Journal of the
American Medical Association (JAMA 2003; 285: 733). I
hope that the CDC
does not continue to expect us to still believe that
the 85% plus of all
CJD cases which are sporadic are all spontaneous,
without route or source.
Until recently, CWD was thought to be confined to the
wild in a small
region in Colorado. But since early 2002, it has been
reported in other
areas, including Wisconsin, South Dakota, and the
Canadian province of
Saskatchewan. Indeed, the occurrence of CWD in states
that were not
endemic previously increased concern about a widespread
outbreak and
possible transmission to people and cattle.
To date, experimental studies have proven that the CWD
agent can be
transmitted to cattle by intracerebral inoculation and
that it can cross
the mucous membranes of the digestive tract to initiate
infection in
lymphoid tissue before invasion of the central nervous
system. Yet the
plausibility of CWD spreading to people has remained
elusive.
Part of the problem seems to stem from the US
surveillance system. CJD
is only reported in those areas known to be endemic
foci of CWD.
Moreover, US authorities have been criticised for not
having performed
enough prionic tests in farm deer and elk.
Although in November last year the US Food and Drug
Administration
issued a directive to state public-health and
agriculture officials
prohibiting material from CWD-positive animals from
being used as an
ingredient in feed for any animal species,
epidemiological control and
research in the USA has been quite different from the
situation in the
UK and Europe regarding BSE.
Getting data on TSEs in the USA from the government is
like pulling
teeth, Singeltary argues. You get it when they want
you to have it,
and only what they want you to have.
Norman Foster, director of the Cognitive Disorders
Clinic at the
University of Michigan (Ann Arbor, MI, USA), says
that current
surveillance of prion disease in people in the USA is
inadequate to
detect whether CWD is occurring in human beings;
adding that, the
cases that we know about are reassuring, because they
do not suggest the
appearance of a new variant of CJD in the USA or
atypical features in
patients that might be exposed to CWD. However, until
we establish a
system that identifies and analyses a high proportion
of suspected prion
disease cases we will not know for sure. The USA should
develop a
system modelled on that established in the UK, he
points out.
Ali Samii, a neurologist at Seattle VA Medical Center
who recently
reported the cases of three hunters two of whom were
friends who died
from pathologically confirmed CJD, says that at present
there are
insufficient data to claim transmission of CWD into
humans; adding that
[only] by asking [the questions of venison consumption
and deer/elk
hunting] in every case can we collect suspect cases and
look into the
plausibility of transmission further. Samii argues that
by making both
doctors and hunters more aware of the possibility of
prions spreading
through eating venison, doctors treating hunters with
dementia can
consider a possible prion disease, and doctors treating
CJD patients
will know to ask whether they ate venison.
CDC spokesman Ermias Belay says that the CDC will not
be investigating
the [Samii] cases because there is no evidence that the
men ate
CWD-infected meat. He notes that although the
likelihood of CWD
jumping the species barrier to infect humans cannot be
ruled out 100%
and that [we] cannot be 100% sure that CWD does not
exist in humans&
the data seeking evidence of CWD transmission to humans
have been very
limited.
http://infection.thelancet.com/journal/journal.isa
>>>he complained in a letter to the Journal of the
American Medical
Association (JAMA 2003; 285: 733). I hope that the CDC
does not
continue to expect us to still believe that the 85%
plus of all CJD
cases which are sporadic are all spontaneous, without
route or source.<<<
actually, that quote was from a more recent article in
the Journal of
Neurology (see below), not the JAMA article...
Re: RE-Monitoring the occurrence of emerging forms of
Creutzfeldt-Jakob
disease in the United States
Email Terry S. Singeltary:
flounder@wt.net
I lost my mother to hvCJD (Heidenhain Variant CJD). I
would like to
comment on the CDC's attempts to monitor the occurrence
of emerging
forms of CJD. Asante, Collinge et al [1] have reported
that BSE
transmission to the 129-methionine genotype can lead to
an alternate
phenotype that is indistinguishable from type 2 PrPSc,
the commonest
sporadic CJD. However, CJD and all human TSEs are not
reportable
nationally. CJD and all human TSEs must be made
reportable in every
state and internationally. I hope that the CDC does not
continue to
expect us to still believe that the 85%+ of all CJD
cases which are
sporadic are all spontaneous, without route/source. We
have many TSEs in
the USA in both animal and man. CWD in deer/elk is
spreading rapidly and
CWD does transmit to mink, ferret, cattle, and squirrel
monkey by
intracerebral inoculation. With the known incubation
periods in other
TSEs, oral transmission studies of CWD may take much
longer. Every
victim/family of CJD/TSEs should be asked about route
and source of this
agent. To prolong this will only spread the agent and
needlessly expose
others. In light of the findings of Asante and Collinge
et al, there
should be drastic measures to safeguard the medical and
surgical arena
from sporadic CJDs and all human TSEs. I only ponder
how many sporadic
CJDs in the USA are type 2 PrPSc?
http://www.neurology.org/cgi/eletters/60/2/176#535
Vol. 285 No. 6, February 14, 2001
Letters
Diagnosis and Reporting of Creutzfeldt-Jakob Disease
Since this article does not have an abstract, we have
provided the first 150 words of the full text and any
section headings.
To the Editor: In their Research Letter, Dr Gibbons and
colleagues1 reported that the annual US death rate due
to Creutzfeldt-Jakob disease (CJD) has been stable
since 1985. These estimates, however, are based only on
reported cases, and do not include misdiagnosed or
preclinical cases. It seems to me that misdiagnosis
alone would drastically change these figures. An
unknown number of persons with a diagnosis of Alzheimer
disease in fact may have CJD, although only a small
number of these patients receive the postmortem
examination necessary to make this diagnosis.
Furthermore, only a few states have made CJD
reportable. Human and animal transmissible spongiform
encephalopathies should be reportable nationwide and
internationally.
Terry S. Singeltary, Sr
Bacliff, Tex
1. Gibbons RV, Holman RC, Belay ED, Schonberger LB.
Creutzfeldt-Jakob disease in the United States:
1979-1998. JAMA. 2000;284:2322-2323. FULL TEXT
To the Editor: At the time of my mother's death,
various diagnoses were advanced such as "rapid
progressive Alzheimer disease," psychosis, and
dementia. Had I not persisted and personally sought and
arranged . . . [Full Text of this Article]
http://jama.ama-assn.org/cgi/content/extract/285/6/733
Full Text
Diagnosis and Reporting of Creutzfeldt-Jakob Disease
Singeltary, Sr et al.
JAMA.2001; 285: 733-734.
http://jama.ama-assn.org/cgi/content/full/285/6/733
HUMAN TSE USA 2005
Animal Prion Diseases Relevant to Humans (unknown types?)
Thu Oct 27, 2005 12:05
71.248.128.109
About Human Prion Diseases /
Animal Prion Diseases Relevant to Humans
Bovine Spongiform Encephalopathy (BSE) is a prion
disease of cattle. Since 1986, when BSE was recognized,
over 180,000 cattle in the UK have developed the
disease, and approximately one to three million are
likely to have been infected with the BSE agent, most
of which were slaughtered for human consumption before
developing signs of the disease. The origin of the
first case of BSE is unknown, but the epidemic was
caused by the recycling of processed waste parts of
cattle, some of which were infected with the BSE agent
and given to other cattle in feed. Control measures
have resulted in the consistent decline of the epidemic
in the UK since 1992. Infected cattle and feed exported
from the UK have resulted in smaller epidemics in other
European countries, where control measures were applied
later.
Compelling evidence indicates that BSE can be
transmitted to humans through the consumption of prion
contaminated meat. BSE-infected individuals eventually
develop vCJD with an incubation time believed to be on
average 10 years. As of November 2004, three cases of
BSE have been reported in North America. One had been
imported to Canada from the UK, one was grown in
Canada, and one discovered in the USA but of Canadian
origin. There has been only one case of vCJD reported
in the USA, but the patient most likely acquired the
disease in the United Kingdom. If current control
measures intended to protect public and animal health
are well enforced, the cattle epidemic should be
largely under control and any remaining risk to humans
through beef consumption should be very small. (For
more details see Smith et al. British Medical Bulletin,
66: 185. 2003.)
Chronic Wasting Disease (CWD) is a prion disease of elk
and deer, both free range and in captivity. CWD is
endemic in areas of Colorado, Wyoming, and Nebraska,
but new foci of this disease have been detected in
Nebraska, South Dakota, New Mexico, Wisconsin,
Mississippi Kansas, Oklahoma, Minnesota, Montana, and
Canada. Since there are an estimated 22 million elk and
deer in the USA and a large number of hunters who
consume elk and deer meat, there is the possibility
that CWD can be transmitted from elk and deer to
humans. As of November 2004, the NPDPSC has examined 26
hunters with a suspected prion disease. However, all of
them appeared to have either typical sporadic or
familial forms of the disease. The NPDPSC coordinates
with the Centers for Disease Control and state health
departments to monitor cases from CWD-endemic areas.
Furthermore, it is doing experimental research on CWD
transmissibility using animal models. (For details see
Sigurdson et al. British Medical Bulletin. 66: 199.
2003 and Belay et al. Emerging Infectious Diseases.
10(6): 977. 2004.)
http://www.cjdsurveillance.com/abouthpd-animal.html
SEE STEADY INCREASE IN SPORADIC CJD IN THE USA FROM
1997 TO 2004. SPORADIC CJD CASES TRIPLED, and that is
with a human TSE surveillance system that is terrible
flawed. in 1997 cases of the _reported_ cases of cjd
were at 54, to 163 _reported_ cases in 2004. see stats
here;
p.s. please note the 47 PENDING CASES to Sept. 2005
p.s. please note the 2005 Prion D. total 120(8)
8=includes 51 type pending, 1 TYPE UNKNOWN ???
p.s. please note sporadic CJD 2002(1) 1=3 TYPE UNKNOWN???
p.s. please note 2004 prion disease (6) 6=7 TYPE
UNKNOWN???
http://www.cjdsurveillance.com/resources-casereport.html
CWD TO HUMANS = sCJD ???
AS implied in the Inset 25 we must not _ASSUME_ that
transmission of BSE to other species will invariably
present pathology typical of a scrapie-like disease.
snip...
http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdf
ATYPICAL TSEs in USA CATTLE AND SHEEP ?
http://www.bseinquiry.gov.uk/files/sc/seac17/tab03.pdf
Infected and Source Flocks
As of August 31, 2005, there were 115 scrapie infected
and source flocks (figure 3). There were 3 new infected
and source flocks reported in August (Figure 4) with a
total of 148 flocks reported for FY 2005 (Figure 5).
The total infected and source flocks that have been
released in FY 2005 are 102 (Figure 6), with 5 flocks
released in August. The ratio of infected and source
flocks released to newly infected and source flocks for
FY 2005 = 0.69 :
1. In addition, as of August 31, 2005, 574 scrapie
cases have been confirmed and reported by the National
Veterinary Services Laboratories (NVSL), of which 122
were RSSS cases (Figure 7). This includes 55 newly
confirmed cases in August 2005 (Figure 8). Fifteen
cases of scrapie in goats have been reported since 1990
(Figure 9). The last goat case was reported in May 2005.
snip...
full text ;
http://www.aphis.usda.gov/vs/nahps/scrapie/monthly_report/monthly-report.html
Published online before print October 20, 2005
Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0502296102
Medical Sciences
A newly identified type of scrapie agent can naturally
infect sheep with resistant PrP genotypes
( sheep prion | transgenic mice )
Annick Le Dur *, Vincent Béringue *, Olivier
Andréoletti , Fabienne Reine *, Thanh Lan Laï *,
Thierry Baron , Bjørn Bratberg ¶, Jean-Luc Vilotte ||,
Pierre Sarradin **, Sylvie L. Benestad ¶, and Hubert
Laude *
*Virologie Immunologie Moléculaires and ||Génétique
Biochimique et Cytogénétique, Institut National de la
Recherche Agronomique, 78350 Jouy-en-Josas, France;
Unité Mixte de Recherche, Institut National de la
Recherche Agronomique-Ecole Nationale Vétérinaire de
Toulouse, Interactions Hôte Agent Pathogène, 31066
Toulouse, France; Agence Française de Sécurité
Sanitaire des Aliments, Unité Agents Transmissibles Non
Conventionnels, 69364 Lyon, France; **Pathologie
Infectieuse et Immunologie, Institut National de la
Recherche Agronomique, 37380 Nouzilly, France; and
¶Department of Pathology, National Veterinary
Institute, 0033 Oslo, Norway
Edited by Stanley B. Prusiner, University of
California, San Francisco, CA, and approved September
12, 2005 (received for review March 21, 2005)
Scrapie in small ruminants belongs to transmissible
spongiform encephalopathies (TSEs), or prion diseases,
a family of fatal neurodegenerative disorders that
affect humans and animals and can transmit within and
between species by ingestion or inoculation. Conversion
of the host-encoded prion protein (PrP), normal
cellular PrP (PrPc), into a misfolded form, abnormal
PrP (PrPSc), plays a key role in TSE transmission and
pathogenesis. The intensified surveillance of scrapie
in the European Union, together with the improvement of
PrPSc detection techniques, has led to the discovery of
a growing number of so-called atypical scrapie cases.
These include clinical Nor98 cases first identified in
Norwegian sheep on the basis of unusual pathological
and PrPSc molecular features and "cases" that produced
discordant responses in the rapid tests currently
applied to the large-scale random screening of
slaughtered or fallen animals. Worryingly, a
substantial proportion of such cases involved sheep
with PrP genotypes known until now to confer natural
resistance to conventional scrapie. Here we report that
both Nor98 and discordant cases, including three sheep
homozygous for the resistant PrPARR allele
(A136R154R171), efficiently transmitted the disease to
transgenic mice expressing ovine PrP, and that they
shared unique biological and biochemical features upon
propagation in mice. These observations support the
view that a truly infectious TSE agent, unrecognized
until recently, infects sheep and goat flocks and may
have important implications in terms of scrapie control
and public health.
--------------------------------------------------------------------------------
Author contributions: H.L. designed research; A.L.D.,
V.B., O.A., F.R., T.L.L., J.-L.V., and H.L. performed
research; T.B., B.B., P.S., and S.L.B. contributed new
reagents/analytic tools; V.B., O.A., and H.L. analyzed
data; and H.L. wrote the paper.
A.L.D. and V.B. contributed equally to this work.
To whom correspondence should be addressed.
Hubert Laude, E-mail: laude@jouy.inra.fr
www.pnas.org/cgi/doi/10.1073/pnas.0502296102
http://www.pnas.org/cgi/content/abstract/0502296102v1
BRITISH MEDICAL JOURNAL
SOMETHING TO CHEW ON
BMJ
http://www.bmj.com/cgi/eletters/319/7220/1312/b#EL2
BMJ
http://www.bmj.com/cgi/eletters/320/7226/8/b#EL1
[Docket No. 03-025IFA] FSIS Prohibition of the Use of
Specified Risk Materials for Human Food and Requirement
for the Disposition of Non-Ambulatory Disabled Cattle
03-025IFA
03-025IFA-2
Terry S. Singeltary
Page 1 of 17
From: Terry S. Singeltary Sr. [flounder9@verizon.net]
Sent: Thursday, September 08, 2005 6:17 PM
To: fsis.regulationscomments@fsis.usda.gov
Subject: [Docket No. 03-025IFA] FSIS Prohibition of the
Use of Specified Risk Materials for Human Food and
Requirements
for the Disposition of Non-Ambulatory Disabled Cattle
Greetings FSIS,
I would kindly like to submit the following to [Docket
No. 03-025IFA] FSIS Prohibition of the Use of Specified
Risk Materials for Human Food and
Requirements for the Disposition of Non-Ambulatory
Disabled Cattle
THE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled Cattle
Broken bones and such may be the first signs of a sub
clinical BSE/TSE Non-Ambulatory Disabled Cattle ;
SUB CLINICAL PRION INFECTION
MRC-43-00
Issued: Monday, 28 August 2000
NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT
RESEARCH
FINDINGS RELEVANT TO CJD AND BSE
Terry S. Singeltary Sr.
P.O. Box 42
Bacliff, Texas USA 77518
9/13/2005
http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdf
Importation of Whole Cuts of Boneless Beef from Japan
[Docket No. 05-004-1] RIN 0579-AB93 TSS SUBMISSION
----- Original Message -----
From: Terry S. Singeltary Sr.
To: docket.oeca@epa.gov ; delores.b.johnson@aphis.usda.gov
Sent: Thursday, August 25, 2005 8:16 AM
Subject: Importation of Whole Cuts of Boneless Beef
from Japan [Docket No. 05-004-1] RIN 0579-AB93 TSS
SUBMISSION
Greetings Dr. Colgrove and Miss Johnson,
Thank you for taking this submission via email. i have
had trouble submitting via the comment page due to the
length of my submission. I was not sure that my file
attachment that i submitted via the ;
EDOCKET: Go to http://www.epa.gov/feddocket
I submitted yesterday, just did not know if the file
reached anyone. so to make sure, I am sending to you to
submit for me.
many thanks,
Terry
From: TSS ()
Subject: Importation of Whole Cuts of Boneless Beef
from Japan [Docket No. 05-004-1] RIN 0579-AB93 TSS
SUBMISSION
Date: August 24, 2005 at 2:47 pm PST
August 24, 2005
Importation of Whole Cuts of Boneless Beef from Japan
[Docket No. 05-004-1] RIN 0579-AB93 TSS SUBMISSION
Greetings APHIS ET AL,
My name is Terry S. Singeltary Sr.
I would kindly like to comment on [Docket No. 05-004-1]
RIN 0579-AB93 ;
PROPOSED RULES
Exportation and importation of animals and animal
products:
Whole cuts of boneless beef from-
Japan,
48494-48500 [05-16422]
[Federal Register: August 18, 2005 (Volume 70, Number 159)]
[Proposed Rules]
[Page 48494-48500]
From the Federal Register Online via GPO Access
[wais.access.gpo.gov]
[DOCID:fr18au05-7]
snip...
Greetings again APHIS ET AL,
THIS is not correct. IN fact, there are several factors
i would like to kindly address.
Muscle tissue has recently been detected with PrPSc
in the peripheral nerves (sciatic nerve, tibial nerve,
vagus nerve) of the 11th BSE
cow in Japan (Yoshifumi Iwamaru et al). also recently,
Aguzzi et al Letter to the Editor
Vet Pathol 42:107-108 (2005), Prusiner et al CDI test
is another example of detection
of the TSE agent in muscle in sCJD, Herbert Budka et al
CJD and inclusion body myositis:
Abundant Disease-Associated Prion Protein in Muscle,
and older studies from Watson
Meldrum et al Scrapie agent in muscle - Pattison I A
(1990), references as follow ;
PrPSc distribution of a natural case of bovine
spongiform encephalopathy
Yoshifumi Iwamaru, Yuka Okubo, Tamako Ikeda, Hiroko
Hayashi, Mori-
kazu Imamura, Takashi Yokoyama and Morikazu Shinagawa
Priori Disease Research Center, National Institute of
Animal Health, 3-1-5
Kannondai, Tsukuba 305-0856 Japan gan@affrc.go.jp
Abstract
Bovine spongiform encephalopathy (BSE) is a disease of
cattle that causes
progressive neurodegeneration of the central nervous
system. Infectivity
of BSE agent is accompanied with an abnormal isoform of
prion protein
(PrPSc).
The specified risk materials (SRM) are tissues
potentially carrying BSE
infectivity. The following tissues are designated as
SRM in Japan: the
skull including the brain and eyes but excluding the
glossa and the masse-
ter muscle, the vertebral column excluding the
vertebrae of the tail, spinal
cord, distal illeum. For a risk management step, the
use of SRM in both
animal feed or human food has been prohibited. However,
detailed
PrPSc distribution remains obscure in BSE cattle and it
has caused con-
troversies about definitions of SRM. Therefore we have
examined PrPSc
distribution in a BSE cattle by Western blotting to
reassess definitions of
SRM.
The 11th BSE case in Japan was detected in fallen stock
surveillance.
The carcass was stocked in the refrigerator. For the
detection of PrPSc,
200 mg of tissue samples were homogenized. Following
collagenase
treatment, samples were digested with proteinase K.
After digestion,
PrPSc was precipitated by sodium phosphotungstate
(PTA). The pellets
were subjected to Western blotting using the standard
procedure.
Anti-prion protein monoclonal antibody (mAb) T2
conjugated horseradish
peroxidase was used for the detection of PrPSc.
PrPSc was detected in brain, spinal cord, dorsal root
ganglia, trigeminal
ganglia, sublingual ganglion, retina. In addition,
PrPSc was also detected
in the peripheral nerves (sciatic nerve, tibial nerve,
vagus nerve).
Our results suggest that the currently accepted
definitions of SRM in
BSE cattle may need to be reexamined. ...
179
T. Kitamoto (Ed.)
PRIONS
Food and Drug Safety
================
ALSO from the International Symposium of Prion Diseases
held in Sendai, October 31, to
November 2, 2004;
Bovine spongiform encephalopathy (BSE) in Japan
snip...
"Furthermore, current studies into transmission of
cases of BSE that are
atypical or that develop in young cattle are expected
to amplify the BSE
prion"
NO. Date conf. Farm Birth place and Date Age at diagnosis
8. 2003.10.6. Fukushima Tochigi 2001.10.13. 23
9. 2003.11.4. Hiroshima Hyogo 2002.1.13. 21
Test results
# 8b, 9c cows Elisa Positive, WB Positive, IHC
negative, histopathology
negative
b = atypical BSE case
c = case of BSE in a young animal
b,c, No PrPSc on IHC, and no spongiform change on histology
International Symposium of Prion Diseases held in
Sendai, October 31, to
November 2, 2004.
The hardback book title is 'PRIONS' Food and Drug Safety
T. Kitamoto (Ed.)
Tetsuyuki Kitamoto
Professor and Chairman
Department of Prion Research
Tohoku University School of Medicine
2-1 SeiryoAoba-ku, Sendai 980-8575, JAPAN
TEL +81-22-717-8147 FAX +81-22-717-8148
e-mail; kitamoto@mail.tains.tohoku.ac.jp
Symposium Secretariat
Kyomi Sasaki
TEL +81-22-717-8233 FAX +81-22-717-7656
e-mail: kvomi-sasaki@mail.